A U.S. federal jury in Delaware ruled on Friday that Parse Biosciences, a Qiagen subsidiary, intentionally infringed three patents exclusively licensed to Scale Biosciences, a unit of 10x Genomics.
The patents in question—U.S. Patent Nos. 10,626,442, 10,982,256, and 11,512,341—were originally licensed by Roche Sequencing Solutions and cover single-cell and spatial biology technologies. The jury rejected Parse’s validity challenges, affirming that all three patents are valid and enforceable.
The jury awarded 10x Genomics more than $4.8 million in damages, calculated at a 14% royalty rate on Parse’s infringing sales of its Evercode Whole Transcriptome products between February 2021 and June 30, 2026. The financial penalty reflects the jury’s determination that Parse’s actions constituted intentional infringement.
10x Genomics intends to pursue additional post-trial remedies, including seeking enhanced damages, attorney fees, and a permanent injunction to prevent further infringement in the United States. The company’s general counsel, Randy Wu, stated that the verdict underscores the protection of innovation through patent rights.
Scale Biosciences co-founder Garry Nolan emphasized the ruling’s significance for inventors, noting that it reaffirms the importance of strong patent protections in scientific advancement. The case was heard in the U.S. District Court for the District of Delaware.
